VEGFA and neoplasm: Bevacizumab is the first targeted anti-tumour angiogenesis drug approved for marketing, which exerts anti-tumour effects by specifically targeting vascular endothelial growth factor (VEGF), and has achieved promising results in the treatment of a wide range of malignancies.